RESUMEN
INTRODUCTION: Hemodialysis uses municipal water that must be strictly purified and sterilized to be used for that procedure. Large amounts of decontaminants are often used, such as chlorine, and if these compounds are not subsequently removed they can be transferred to the blood of patients causing complications including methemoglobinemia. METHODS: In this case series study, dialysis patients in one unit were evaluated. We reviewed clinical characteristics and laboratory findings obtained on the day when the water supply was disinfected with chlorine, with the aim to quantify methemoglobin concentrations. Our objective was to characterize the clinical presentation and management of patients who presented with methemoglobinemia on a specific index day. We also reviewed reported cases in the literature regarding this underreported complication. RESULTS: Eight patients who presented with chlorine intoxication were evaluated. The methemoglobin concentrations were between 1.3% and 7.9% (reference value 0-1%). We believe this to be caused by water containing 0.78 mg/L of total chlorine. Seven patients presented with cyanosis, 4 with dizziness, 6 with dark brown blood, 4 with dyspnea, and 4 with headache and hemolytic anemia. Subjects were treated with supplemental oxygen, methylene blue, intravenous vitamin C, blood transfusions, and increased doses of erythropoietin. No patient died, and all continued with their usual hemodialysis sessions. CONCLUSION: Acute chlorine intoxication transferred by the water used during hemodialysis sessions can present with methemoglobinemia accompanied by cyanosis, oxygen desaturation, and hemolytic anemia. Chlorine levels should be carefully monitored in the water used for hemodialysis treatment.
Asunto(s)
Anemia Hemolítica , Metahemoglobinemia , Humanos , Metahemoglobinemia/inducido químicamente , Metahemoglobinemia/terapia , Metahemoglobina/uso terapéutico , Cloro/toxicidad , Diálisis Renal/efectos adversos , Cianosis/complicaciones , Cloruros , Anemia Hemolítica/complicaciones , Oxígeno , AguaRESUMEN
BACKGROUND Hyperkalemia is an important cause of arrhythmias and a medical emergency that requires urgent treatment. The etiology is usually multifactorial. It is most frequently caused by impaired potassium secretion, followed by transcellular potassium shifts and an increased potassium load. CASE REPORT A male newborn developed monomorphic ventricular tachycardia 2 hours after birth. He was born in the 35th week of gestation by urgent C-section following placental abruption. Laboratory results showed hemolytic anemia (Hb 99 g/L, Hct 0.31) with increased bilirubin levels and reticulocytosis, thrombocytopenia (39×109/L), hypoglycemia (0.8 mmol/L), and severe hyperkalemia (9.8 mmol/L). Umbilical artery blood gas analysis showed hypoxemia with acidosis (pO2 3.8 kPa, pH 7.21, pCO2 7.84 kPa, HCO3 23.3 mmol/L, BE -5 mmol/L). Creatinine (102 µmol/L) and urea (9.8 mmol/L) were mildly elevated. Inflammatory markers were also increased (CRP 26 mg/L, blood leukocyte count 24×109/L). Early-onset sepsis, caused by Candida albicans, was confirmed approximately 24 hours after birth. Non-invasive ventilation with 35-40% O2 was necessary due to transient tachypnea. The neonate received a transfusion of packed red blood cells, a 10% glucose infusion, and empirical antibiotic therapy. Hyperkalemia accompanied by arrhythmias was treated with calcium gluconate, insulin, Sorbisterit enema, and, finally, by exchange transfusion. CONCLUSIONS We report a case of severe hyperkalemia in a newborn immediately after birth. Making a decision as early as possible regarding exchange transfusion is essential in patients with hyperkalemia with electrocardiogram changes and hemodynamic instability.
Asunto(s)
Hiperpotasemia/diagnóstico , Taquicardia Ventricular/etiología , Anemia Hemolítica/complicaciones , Bilirrubina/sangre , Candidiasis/diagnóstico , Humanos , Hiperpotasemia/terapia , Hipoglucemia/complicaciones , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/diagnóstico , Masculino , Sepsis Neonatal/microbiología , Reticulocitosis , Trombocitopenia/complicacionesRESUMEN
INTRODUCTION: Hemolytic disease of the fetus and newborn (HDFN) occurs when fetal and neonatal erythroid cells are destroyed by maternal erythrocyte alloantibodies, it leads to anemia and hydrops in the fetus, and hyperbilirubinemia and kernicterus in the newborn. Postnatal care consists of intensive phototherapy and exchange transfusions to treat severe hyperbilirubinemia and top-up transfusions to treat early and late anemia. Other postnatal complications have been reported such as thrombocytopenia, iron overload and cholestasis requiring specific management. Areas covered: This review focusses on the current neonatal management and outcome of hemolytic disease and discusses postnatal treatment options as well as literature on long-term neurodevelopmental outcome. Expert commentary: Despite major advances in neonatal management, multiple issues have to be addressed to optimize postnatal management and completely eradicate kernicterus. Except for strict adherence to guidelines, improvement could be achieved by clarifying the epidemiology and pathophysiology of HDFN. Several pharmacotherapeutic agents should be further researched as alternative treatment options in hyperbilirubinemia, including immunoglobulins, albumin, phenobarbital, metalloporphyrins, zinc, clofibrate and prebiotics. Larger trials are warranted to evaluate EPO, folate and vitamin E in neonates. Long-term follow-up studies are needed in HDFN, especially on thrombocytopenia, iron overload and cholestasis.
Asunto(s)
Anemia Hemolítica/inmunología , Anemia Hemolítica/terapia , Anemia Neonatal/inmunología , Anemia Neonatal/terapia , Isoanticuerpos/inmunología , Anemia Hemolítica/complicaciones , Anemia Hemolítica/diagnóstico , Anemia Neonatal/complicaciones , Anemia Neonatal/diagnóstico , Terapia Combinada , Manejo de la Enfermedad , Recambio Total de Sangre , Fluidoterapia/métodos , Humanos , Hiperbilirrubinemia/diagnóstico , Hiperbilirrubinemia/etiología , Hiperbilirrubinemia/terapia , Inmunoglobulinas Intravenosas , Recién Nacido , Kernicterus/diagnóstico , Kernicterus/etiología , Kernicterus/terapia , Factores de Tiempo , Resultado del TratamientoRESUMEN
Background Phenylhydrazine (PHE) in experimental animal models has been widely reported to cause haemolytic anaemia, via the induction of oxidative stress and thus causing deleterious cardiovascular complications. Hence, this study was designed to evaluate the possible modulatory role of melatonin (MLT) or vitamin C when co-administered with PHE. Methods Anaemia was established with PHE administration. MLT or vitamin C was co-administered with PHE. Haematological parameters, markers of oxidative stress, enzymic and non-enzymic antioxidants, blood pressure and electrocardiograms were assessed. Results PHE administration led to a significant (p<0.05) increase in malondialdehyde (MDA), and hydrogen peroxide (H2O2) generated in cardiac, renal and red blood cell (RBC) lysates. PHE also significantly reduced the activity of glutathione peroxidase (GPx), superoxide dismutase (SOD) and reduced glutathione (GSH) contents, respectively. The RBC counts, haemoglobin (Hb) concentration and packed cell volume (PCV) were also significantly reduced following the administration of PHE. Furthermore, the systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial blood pressure (MABP) increased significantly in rats administered PHE alone. Similarly, PHE administration led to a significant drop in heart rate but prolonged QRS, QT and QTc interval. Pathology of the heart and kidney was also observed in PHE treated group. However, treatment with MLT and vitamin C improved enzymic and non-enzymic antioxidant system together with the restoration of SBP, DBP and MABP to near normal. The architectural anarchy observed in the heart and kidney of PHE administered rats was reversed to some extent. Conclusions Hence, MLT and vitamin C could be employed as therapeutic targets in various cardiovascular diseases and its complications.
Asunto(s)
Anemia Hemolítica/tratamiento farmacológico , Antioxidantes/uso terapéutico , Ácido Ascórbico/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Hipertensión/prevención & control , Melatonina/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Anemia Hemolítica/sangre , Anemia Hemolítica/inducido químicamente , Anemia Hemolítica/complicaciones , Animales , Antioxidantes/metabolismo , Antioxidantes/farmacología , Ácido Ascórbico/farmacología , Catalasa/metabolismo , Eritrocitos/metabolismo , Glutatión/metabolismo , Glutatión Peroxidasa/metabolismo , Corazón/efectos de los fármacos , Hemoglobinas/metabolismo , Peróxido de Hidrógeno/sangre , Hipertensión/sangre , Hipertensión/etiología , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Masculino , Malondialdehído/sangre , Melatonina/farmacología , Miocardio/metabolismo , Miocardio/patología , Fenilhidrazinas , Ratas Wistar , Superóxido Dismutasa/metabolismo , Vitaminas/farmacología , Vitaminas/uso terapéuticoRESUMEN
La enfermedad de Wilson es un desorden autosómico recesivo del metabolismo del cobre.Se reporta un caso de cirrosis hepática y anemia hemolítica por enfermedad de Wilson en una adolescente de 13 años de edad. Debuta con cuadro sugestivo de infección urinaria, leucocituria, hematuria, acompañada de íctero de piel y mucosas, hepatomegalia ligera, vómitos y toma del estado general por lo que requiere cuidados intensivos pediátricos durante 5 días. Se le realizaron análisis complementarios compatibles con anemia hemolítica severa, Hb. 53 g/L Hto. 0,17 l/L, reticulocitosis de 180 x103, prueba de Coombs negativa, alteraciones del coagulograma y ligera elevación de las aminotransferasas. El estudio hepático mostró cifras de ceruloplasmina en 0,07 g/L, cobre en orina basal 9,13 µmol/día, cobre el tejido hepático 9,54 µg/g de tejido seco, presencia de anillo de Kayser Fleischer en lámpara de hendidura, laparoscopia con aspecto de una cirrosis hepática micronodular y biopsia hepática con una cirrosis micronodular secundaria a una enfermedad de Wilson.El diagnostico de enfermedad de Wilson deberá tenerse presente en todos aquellos niños que presenten una enfermedad hepática crónica o de evolución tórpida cuya etiología no aparezca clara, de tal manera de evitar el compromiso neurológico que habitualmente es más tardío(AU)
Wilson Disease (WD) is a recessive autosomal disorder in copper metabolism. A hepatic cirrhosis and hemolytic anemia is reported due to WD, in an female adolescent of age 13, with family antecedent of a sister with WD. She debuts presenting what seems to be a urinary infection, leukocyturia, hematuria, together with skin and mucosas icterus, mild hepatomegaly, vomits and generalized state of disease, reason why she requires pediatric intensive care for five days. Complementary analysis were carried out, compatibles with severe hemolytic anemia, HB. 53 g/L, Hto. 0.17i/L, reticulocytosis of 180X103, negative Coombs test, coagulogram alterations, and mild elevation of aminotransferases. The hepatic study show ciphers of ceruloplasmin in 0.07 g/L, copper in basal urine 9.13 µmol per day, copper in hepatic tissue 9,54 µg/g in dry tissue, Kayser Fleischer Ring in slit lamp, laparoscopy with aspect of a micronodular hepatic cirrhosis and liver biopsy with a secondary micronodular cirrhosis to a WD. The WD diagnosis should be taken into account in all children with a crhonic liver disease or torpid evoluction whose etiology is not clear, so that the normally later neurologic compromise may be avoided
Asunto(s)
Humanos , Adolescente , Degeneración Hepatolenticular/complicaciones , Degeneración Hepatolenticular/metabolismo , Degeneración Hepatolenticular/orina , Anemia Hemolítica/complicacionesRESUMEN
Glutathione synthetase deficiency (GSSD) is a rare disorder of glutathione metabolism with varying clinical severity. Patients may present with hemolytic anemia alone or together with acidosis and central nervous system impairment. Diagnosis is made by clinical presentation and detection of elevated concentrations of 5-oxoproline in urine and low glutathione synthetase activity in erythrocytes or cultured skin fibroblasts. The prognosis seems to depend on early diagnosis and treatment. We report a 4 months old Tunisian male infant who presented with severe metabolic acidosis with high anion gap and hemolytic anemia. High level of 5-oxoproline was detected in her urine and diagnosis of GSSD was made. Treatment consists of the correction of acidosis, blood transfusion, and supplementation with antioxidants. He died of severe metabolic acidosis and sepsis at the age of 15 months.
Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos/diagnóstico , Anemia Hemolítica/diagnóstico , Glutatión Sintasa/deficiencia , Glutatión Sintasa/orina , Ácido Pirrolidona Carboxílico/orina , Acidosis/complicaciones , Errores Innatos del Metabolismo de los Aminoácidos/complicaciones , Anemia Hemolítica/complicaciones , Antioxidantes/química , Eritrocitos/enzimología , Resultado Fatal , Fiebre/complicaciones , Fibroblastos/enzimología , Humanos , Lactante , Infecciones por Klebsiella/complicaciones , Masculino , Sepsis/complicaciones , Piel/citología , Resultado del Tratamiento , TúnezRESUMEN
ALX-0681 is a therapeutic Nanobody targeting the A1-domain of VWF. It inhibits the interaction between ultra-large VWF and platelet GpIb-IX-V, which plays a crucial role in the pathogenesis of thrombotic thrombocytopenic purpura (TTP). In the present study, we report the efficacy and safety profile of ALX-0681 in a baboon model of acquired TTP. In this model, acute episodes of TTP are induced by administration of an ADAMTS13-inhibiting mAb. ALX-0681 completely prevented the rapid onset of severe thrombocytopenia and schistocytic hemolytic anemia. After induction of TTP, platelet counts also rapidly recovered on administration of ALX-0681. This effect was corroborated by the full neutralization of VWF activity. The schistocytic hemolytic anemia was also halted and partially reversed by ALX-0681 treatment. Brain CT scans and post mortem analysis did not reveal any sign of bleeding, suggesting that complete neutralization of VWF by ALX-0681 under conditions of thrombocytopenia was not linked with an excessive bleeding risk. The results obtained in this study demonstrate that ALX-0681 can successfully treat and prevent the most important hallmarks of acquired TTP without evidence of a severe bleeding risk. Therefore, ALX-0681 offers an attractive new therapeutic option for acquired TTP in the clinical setting.
Asunto(s)
Anemia Hemolítica/tratamiento farmacológico , Anticuerpos Monoclonales/uso terapéutico , Fibrinolíticos/uso terapéutico , Púrpura Trombocitopénica Trombótica/tratamiento farmacológico , Factor de von Willebrand/antagonistas & inhibidores , Proteínas ADAM/antagonistas & inhibidores , Proteínas ADAM/metabolismo , Anemia Hemolítica/complicaciones , Anemia Hemolítica/metabolismo , Anemia Hemolítica/patología , Animales , Anticuerpos Monoclonales/farmacología , Plaquetas/efectos de los fármacos , Plaquetas/metabolismo , Plaquetas/patología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Fibrinolíticos/farmacología , Masculino , Imagen Multimodal , Papio , Recuento de Plaquetas , Tomografía de Emisión de Positrones , Púrpura Trombocitopénica Trombótica/complicaciones , Púrpura Trombocitopénica Trombótica/metabolismo , Púrpura Trombocitopénica Trombótica/patología , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Factor de von Willebrand/metabolismoRESUMEN
La enfermedad hemolítica perinatal se caracteriza por la aparición de anticuerpos contra la membrana del glóbulo rojo fetal lo que lleva a anemia fetal. La medición con Doppler del peak sistólico de la arteria cerebral media (ACM) se correlaciona directamente con el grado de anemia fetal y por lo tanto con la gravedad de la enfermedad hemolítica. Se realizó un seguimiento de 20 pacientes Rh (-) sensibilizadas, atendidas en el Servicio de Ginecología del Hospital San Juan de Dios con mediciones seriadas del peak sistólico de la ACM. El 100 por ciento de los valores observados para el peak sistólico de la ACM estuvieron en rango normal para la edad gestacional, incluso en aquellos fetos y recién nacidos que necesitaron recambio sanguíneo y fototerapia postparto, lo que se contrapone con lo descrito en la literatura. Posibles causas de este hallazgo pueden ser: mala toma del peak sistólico, curva demasiado exigente para los casos estudiados y muestra demasiado pequeña. Se requiere seguimiento més largo y una muestra més numerosa. Se realizará un seguimiento con un grupo mayor de pacientes.
Asunto(s)
Humanos , Femenino , Embarazo , Anemia Hemolítica/complicaciones , Eritroblastosis Fetal/etiología , Arteria Cerebral Media , Sangre Fetal/inmunología , Ultrasonografía DopplerRESUMEN
Anaemia is not a disease in itself. It is a sign of a single or multiple diseases. Anaemia is said to exist when the haemoglobin concentration is below normal for the age and sex of an individual. The synthesis and normal circulatory level of haemoglobin in any given individual depend on factors such as an adequate supply of haemopoietic nutrients, normal functioning of bone marrow, and proper utilization of haemoglobin. Based on these factors anemia can be broadly grouped into three categories: 1. Anaemia due to lack of haemopoietic nutrients (nutritional anemia) 2. Anaemia due to bone marrow dysfunction (aplastic anaemia) 3. Anaemia due to excessive breakdown of red blood cells (haemolytic anaemia) (AU)
Asunto(s)
Humanos , Anemias Nutricionales/complicaciones , Anemia Megaloblástica/clasificación , Anemia Megaloblástica/diagnóstico , Anemia Megaloblástica/prevención & control , Anemia Aplásica/clasificación , Anemia Aplásica/etiología , Anemia Aplásica/diagnóstico , Anemia Aplásica/tratamiento farmacológico , Hemólisis/efectos de los fármacos , Anemia Hemolítica/complicaciones , Anemia Hemolítica/diagnóstico , Anemia Hemolítica/etiología , Hemoglobinuria Paroxística/diagnóstico , Talasemia/diagnóstico , Talasemia/etiologíaRESUMEN
A rare case of hemolytic anemia complicated with Behçet's disease and myelodysplastic syndrome (MDS) is described. A 41-year old woman suffering from hemolytic anemia was admitted in July of 1988 with right lower abdominal pain and a high fever. Her anemia was first pointed out in 1962 (at age 15), and diagnosed as hemolytic anemia in 1977 by a full hematological examination showing erythro-hyperplasia in bone marrow, Coomb's test was negative and corticosteroid therapy failed to improve her anemia. She had also been suffering from recurrent stomatitis and genital ulcer since the delivery of her first baby in July, 1972. Barium enema was performed and revealed a simple deep ulcer at the terminal ileum. Bone marrow examination showed morphological abnormalities of granulocytic and erythrocytic series. We thereby diagnosed her illness as incomplete Behçet's disease and MDS associated with hemolytic anemia. She was treated by ubenimex, blood transfusion and intravenous alimentation with discontinuing oral intake, and there was a satisfactory improvement in pancytopenia and ulcer.
Asunto(s)
Anemia Hemolítica/complicaciones , Síndrome de Behçet/etiología , Síndromes Mielodisplásicos/etiología , Adulto , Femenino , Humanos , Leucina/análogos & derivados , Leucina/uso terapéutico , Síndromes Mielodisplásicos/tratamiento farmacológicoRESUMEN
The unique association of idiopathic diffuse membranous nephropathy and micro-angiopathic haemolytic anaemia and thrombocytopenia is described. A 7 year old Vietnamese boy with a 1-month history of anaemia resistant to oral iron supplements presented with acute onset of nephrotic syndrome. Investigations revealed a micro-angiopathic haemolytic anaemia and thrombocytopenia. There was no associated oliguria or uraemia. Diffuse membranous nephropathy was diagnosed by renal biopsy. Apart from a fourfold rise in enterovirus titres, no underlying cause for the haematological or glomerular abnormalities was found. There was an apparent, partial haematological response to fresh frozen plasma infusions, but not to Vitamin E.
Asunto(s)
Anemia Hemolítica/complicaciones , Glomerulonefritis Membranosa/complicaciones , Síndrome Nefrótico/etiología , Trombocitopenia/complicaciones , Niño , Estudios de Seguimiento , Glomerulonefritis Membranosa/patología , Humanos , Masculino , Síndrome Nefrótico/patologíaRESUMEN
Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic syndrome (HUS) have in common a microangiopathic hemolytic anemia involving disseminated platelet aggregation and endothelial damage of the microvasculature mainly of the brain (TTP) and kidney (HUS). The underlying pathomechanism still remains unclear. The disease takes an acute, dramatic and frequently fatal course. Unfortunately a broadly approved therapeutic regimen is still lacking since the rarity of TTP and HUS makes study of a large group of patients impossible. We have observed and treated 14 patients with TTP and HUS during a period of 9 years. Most of the cases have been triggered by infectious diseases and pregnancy. Diagnostic cornerstones were hemolytic anemia, schistocytes on peripheral blood smears and consumption thrombocytopenia. Renal and cerebral symptoms were observed regularly, whereas lesions of the pancreas, liver and heart were much less frequent. The treatment included plasma transfusion (47%), plasma exchange (42%), high dose corticosteroids (74%), antiplatelet agents (53%), vitamin E (32%) and vincristin (11%). The outcome of 19 episodes of TTP or HUS was as follows: in 78% complete recovery, in 11% persistence of impaired renal function, and in 11% death. From analysis of our cases it is concluded that plasma transfusions and high dose corticosteroids improve the prognosis of TTP and HUS significantly.
Asunto(s)
Anemia Hemolítica/complicaciones , Síndrome Hemolítico-Urémico/complicaciones , Púrpura Trombocitopénica Trombótica/complicaciones , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Anemia Hemolítica/fisiopatología , Anemia Hemolítica/terapia , Anticoagulantes/uso terapéutico , Transfusión Sanguínea , Femenino , Síndrome Hemolítico-Urémico/fisiopatología , Síndrome Hemolítico-Urémico/terapia , Humanos , Masculino , Persona de Mediana Edad , Intercambio Plasmático , Púrpura Trombocitopénica Trombótica/fisiopatología , Púrpura Trombocitopénica Trombótica/terapia , Síndrome , Vincristina/uso terapéuticoAsunto(s)
Plaquetas/patología , Trombocitopenia/etiología , Corticoesteroides/uso terapéutico , Anemia Hemolítica/sangre , Anemia Hemolítica/complicaciones , Animales , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/complicaciones , Niño , Preescolar , Coagulación Intravascular Diseminada/sangre , Enterocolitis Seudomembranosa/sangre , Enterocolitis Seudomembranosa/complicaciones , Femenino , Retardo del Crecimiento Fetal/sangre , Retardo del Crecimiento Fetal/complicaciones , Hemangioma/sangre , Hemangioma/complicaciones , Síndrome Hemolítico-Urémico/sangre , Humanos , Lactante , Recién Nacido , Enfermedades del Recién Nacido/sangre , Fototerapia/efectos adversos , Recuento de Plaquetas , Embarazo , Complicaciones Hematológicas del Embarazo/sangre , Púrpura Trombocitopénica/sangre , Púrpura Trombocitopénica/tratamiento farmacológico , Púrpura Trombocitopénica/inmunología , Conejos , Trombocitopenia/congénito , Trombocitopenia/inmunología , Ácido Valproico/efectos adversosRESUMEN
Serum vitamin E concentrations were determined in 60 term and 26 premature infants during the first 2 months of life. All infants received commercial milk formula containing vitamin E. In addition, premature infants older than 10 days were given vitamin E orally as a multivitamin preparation. Thus, daily intake of vitamin E was nearly 1.2 mg/kg body weight in term infants and 2--3 mg/kg body weight in premature infants. In term infants serum levels of vitamin E rose from 2.6 mg/l (cord blood) to 7.0 mg/l (3rd--13th day) and 9.1 mg/l (16th--25th day) and remained at 10 mg/l (in the second month of life). Hemoglobin concentration and red cell number decreased continuously due to physiological anemia of infancy. In premature infants mean values of vitamin E were the same as in term infants. Vitamin E deficiency with hemolytic anemia could be demonstrated in a 2 months old infant suffering from cystic fibrosis.